Vol 39, Issue 7

Approximately 6.5 million Americans are living with Alzheimer disease today, and that number is projected to rise to about 13 million by 2050.

A frequent criticism of psychiatry: psychiatrists do not learn, practice, or value psychotherapy. Is it true?

Exploring the association between methamphetamine use and the development of psychotic symptoms, such as paranoid delusions, ideas of reference, and auditory hallucinations.

It is time for gender-sensitive first-episode psychosis services.

What happens when a clinician is faced with addiction in their own family?

Researchers performed a nationwide register-based study of primary antipsychotic nonadherence in schizophrenia.

Did you miss the American Psychiatric Association 2022 Annual Meeting? We've got you covered.

Treatment deserts are adding fuel to the fire of the opioid crisis.

"We call them The Not Dead when they crumple in an easy chair after chemo..."

"The fact is that these patients have a huge capacity to improve their lives, far more than the average person. The work done with them in a clinical setting echoes throughout their families and communities and can be some of the most rewarding work for clinicians."

An effect size tells us how much difference a treatment makes.

What are the biggest challenges facing both clinicians and patients, and how can we address them?

In this CME, review the pathophysiology of anti-N-methyl-D-aspartate receptor encephalitis.

The July issue of Psychiatric Times provides insights on clinical challenges and more.

"The young and exciting field of psychiatric pharmacogenomics is providing a third pillar of understanding to aid in our competent and informed prescribing of drugs, joining the more well-established pillars of pharmacokinetics and pharmacodynamics."

What does the Psychiatric Times Editor in Chief think about 988?

The new suicide hotline is launching July 16. Are we ready for it?